Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
Evidence exists that interleukin (IL)-1β is involved in pancreatic β-cell damage, whereas TNF-α appears to be a key molecule in peripheral insulin resistance. Although increased plasma levels of IL-6 are seen in individuals with type 2 diabetes, mechanistic studies suggest that moderate acute elevations in IL-6, as provoked by exercise, exert anti-inflammatory effects by an inhibition of TNF-α and by stimulating IL-1 receptor antagonist (ra), thereby limiting IL-1β signaling. A number of medical treatments have anti-inflammatory effects. IL-1 antagonists have been tested in clinical studies and appear very promising. Also, there is a potential for anti-TNF-α strategies and salsalate has been shown to improve insulin sensitivity in clinical trials. Furthermore, the anti-inflammatory potential of statins, antagonists of the renin-angiotensin system, and glucose-lowering agents are discussed. While waiting for the outcome of long-term clinical pharmacological trials, it should be emphasized that physical activity represents a natural strong anti-inflammatory intervention with little or no side effects.
Original language | English |
---|---|
Article number | 82 |
Journal | Current Diabetes Reports |
Volume | 15 |
Pages (from-to) | 1-9 |
Number of pages | 9 |
ISSN | 1534-4827 |
DOIs | |
Publication status | Published - Oct 2015 |
- Animals, Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Humans, Inflammation, Life Style, Motor Activity, Neuropeptides
Research areas
ID: 162757614